Baseline characteristics of patients enrolled in TT1, TT2, and TT3 according to response category*
| Factor . | TT1 . | TT2 . | TT3 . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sus-CR . | los-CR . | non-CR . | P . | sus-CR . | los-CR . | non-CR . | P . | sus-CR . | los-CR . | non-CR . | P . | |
| Age ≥ 65 y | 3/44 (7) | 0/33 (0) | 8/88 (9) | .203 | 42/258 (16) | 10/37 (27) | 44/218 (20) | .224 | 33/138 (24) | 0/4 (0) | 20/62 (32) | .225 |
| Albumin < 3.5 g/dL | 9/44 (20) | 7/33 (21) | 26/88 (30) | .434 | 35/257 (14) | 11/37 (30) | 35/216 (16) | .043 | 21/138 (15) | 0/4 (0) | 12/62 (19) | .515 |
| B2M ≥ 3.5 mg/L | 12/44 (27) | 14/33 (42) | 32/86 (37) | .350 | 79/258 (31) | 19/37 (51) | 75/218 (34) | .043 | 55/138 (40) | 2/4 (50) | 27/62 (44) | .830 |
| B2M > 5.5 mg/L | 6/44 (14) | 2/33 (6) | 13/86 (15) | .412 | 37/258 (14) | 9/37 (24) | 32/218 (15) | .275 | 17/138 (12) | 2/4 (50) | 15/62 (24) | .022 |
| CRP ≥ 4 mg/L | 17/43 (40) | 18/33 (55) | 29/84 (35) | .138 | 144/255 (56) | 24/37 (65) | 105/213 (49) | .118 | 78/138 (57) | 4/4 (100) | 33/61 (54) | .200 |
| CRP ≥ 8 mg/L | 11/43 (26) | 10/33 (30) | 19/84 (23) | .685 | 111/255 (44) | 15/37 (41) | 68/213 (32) | .035 | 39/138 (28) | 2/4 (50) | 19/61 (31) | .610 |
| Creatinine ≥ 2 mg/dL | 3/44 (7) | 1/33 (3) | 8/88 (9) | .515 | 22/251 (9) | 3/36 (8) | 16/214 (7) | .880 | 4/138 (3) | 1/4 (25) | 9/62 (15) | .004 |
| LDH ≥ 190 U/L | 7/43 (16) | 12/33 (36) | 12/88 (14) | .015 | 77/257 (30) | 17/37 (46) | 46/217 (21) | .003 | 29/138 (21) | 2/4 (50) | 15/62 (24) | .366 |
| CAs† | 10/43 (23) | 11/33 (33) | 24/79 (30) | .588 | 54/257 (21) | 9/37 (24) | 59/214 (28) | .252 | 41/138 (30) | 1/4 (25) | 14/61 (23) | .612 |
| GEP high-risk | NA | NA | NA | NA | 11/139 (8) | 4/18 (22) | 3/116 (3) | .005 | 12/124 (10) | 2/3 (67) | 5/58 (9) | .005 |
| GEP CD-1 subgroup | NA | NA | NA | NA | 13/139 (9) | 2/18 (11) | 4/116 (3) | .141 | 8/124 (6) | 1/3 (33) | 1/58 (2) | .041 |
| GEP CD-2 subgroup | NA | NA | NA | NA | 17/139 (12) | 0/18 (0) | 21/116 (18) | .085 | 7/124 (6) | 0/3 (0) | 11/58 (19) | .016 |
| GEP HY subgroup | NA | NA | NA | NA | 37/139 (27) | 3/18 (17) | 41/116 (35) | .145 | 36/124 (29) | 0/3 (0) | 20/58 (34) | .391 |
| GEP LB subgroup | NA | NA | NA | NA | 16/139 (12) | 0/18 (0) | 11/116 (9) | .300 | 15/124 (12) | 0/3 (0) | 8/58 (14) | .764 |
| GEP MF subgroup | NA | NA | NA | NA | 6/139 (4) | 3/18 (17) | 4/116 (3) | .047 | 9/124 (7) | 2/3 (67) | 4/58 (7) | <.001 |
| GEP MS subgroup | NA | NA | NA | NA | 9/139 (6) | 3/18 (17) | 16/116 (14) | .103 | 15/124 (12) | 0/3 (0) | 7/58 (12) | .814 |
| GEP MY subgroup | NA | NA | NA | NA | 27/139 (19) | 5/18 (28) | 15/116 (13) | .185 | 23/124 (19) | 0/3 (0) | 6/58 (10) | .275 |
| GEP PR subgroup | NA | NA | NA | NA | 14/139 (10) | 2/18 (11) | 4/116 (3) | .106 | 11/124 (9) | 0/3 (0) | 1/58 (2) | .170 |
| GEP MGUS-like | NA | NA | NA | NA | 45/139 (32) | 2/18 (11) | 44/116 (38) | .076 | 32/124 (26) | 1/3 (33) | 15/58 (26) | .958 |
| Factor . | TT1 . | TT2 . | TT3 . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sus-CR . | los-CR . | non-CR . | P . | sus-CR . | los-CR . | non-CR . | P . | sus-CR . | los-CR . | non-CR . | P . | |
| Age ≥ 65 y | 3/44 (7) | 0/33 (0) | 8/88 (9) | .203 | 42/258 (16) | 10/37 (27) | 44/218 (20) | .224 | 33/138 (24) | 0/4 (0) | 20/62 (32) | .225 |
| Albumin < 3.5 g/dL | 9/44 (20) | 7/33 (21) | 26/88 (30) | .434 | 35/257 (14) | 11/37 (30) | 35/216 (16) | .043 | 21/138 (15) | 0/4 (0) | 12/62 (19) | .515 |
| B2M ≥ 3.5 mg/L | 12/44 (27) | 14/33 (42) | 32/86 (37) | .350 | 79/258 (31) | 19/37 (51) | 75/218 (34) | .043 | 55/138 (40) | 2/4 (50) | 27/62 (44) | .830 |
| B2M > 5.5 mg/L | 6/44 (14) | 2/33 (6) | 13/86 (15) | .412 | 37/258 (14) | 9/37 (24) | 32/218 (15) | .275 | 17/138 (12) | 2/4 (50) | 15/62 (24) | .022 |
| CRP ≥ 4 mg/L | 17/43 (40) | 18/33 (55) | 29/84 (35) | .138 | 144/255 (56) | 24/37 (65) | 105/213 (49) | .118 | 78/138 (57) | 4/4 (100) | 33/61 (54) | .200 |
| CRP ≥ 8 mg/L | 11/43 (26) | 10/33 (30) | 19/84 (23) | .685 | 111/255 (44) | 15/37 (41) | 68/213 (32) | .035 | 39/138 (28) | 2/4 (50) | 19/61 (31) | .610 |
| Creatinine ≥ 2 mg/dL | 3/44 (7) | 1/33 (3) | 8/88 (9) | .515 | 22/251 (9) | 3/36 (8) | 16/214 (7) | .880 | 4/138 (3) | 1/4 (25) | 9/62 (15) | .004 |
| LDH ≥ 190 U/L | 7/43 (16) | 12/33 (36) | 12/88 (14) | .015 | 77/257 (30) | 17/37 (46) | 46/217 (21) | .003 | 29/138 (21) | 2/4 (50) | 15/62 (24) | .366 |
| CAs† | 10/43 (23) | 11/33 (33) | 24/79 (30) | .588 | 54/257 (21) | 9/37 (24) | 59/214 (28) | .252 | 41/138 (30) | 1/4 (25) | 14/61 (23) | .612 |
| GEP high-risk | NA | NA | NA | NA | 11/139 (8) | 4/18 (22) | 3/116 (3) | .005 | 12/124 (10) | 2/3 (67) | 5/58 (9) | .005 |
| GEP CD-1 subgroup | NA | NA | NA | NA | 13/139 (9) | 2/18 (11) | 4/116 (3) | .141 | 8/124 (6) | 1/3 (33) | 1/58 (2) | .041 |
| GEP CD-2 subgroup | NA | NA | NA | NA | 17/139 (12) | 0/18 (0) | 21/116 (18) | .085 | 7/124 (6) | 0/3 (0) | 11/58 (19) | .016 |
| GEP HY subgroup | NA | NA | NA | NA | 37/139 (27) | 3/18 (17) | 41/116 (35) | .145 | 36/124 (29) | 0/3 (0) | 20/58 (34) | .391 |
| GEP LB subgroup | NA | NA | NA | NA | 16/139 (12) | 0/18 (0) | 11/116 (9) | .300 | 15/124 (12) | 0/3 (0) | 8/58 (14) | .764 |
| GEP MF subgroup | NA | NA | NA | NA | 6/139 (4) | 3/18 (17) | 4/116 (3) | .047 | 9/124 (7) | 2/3 (67) | 4/58 (7) | <.001 |
| GEP MS subgroup | NA | NA | NA | NA | 9/139 (6) | 3/18 (17) | 16/116 (14) | .103 | 15/124 (12) | 0/3 (0) | 7/58 (12) | .814 |
| GEP MY subgroup | NA | NA | NA | NA | 27/139 (19) | 5/18 (28) | 15/116 (13) | .185 | 23/124 (19) | 0/3 (0) | 6/58 (10) | .275 |
| GEP PR subgroup | NA | NA | NA | NA | 14/139 (10) | 2/18 (11) | 4/116 (3) | .106 | 11/124 (9) | 0/3 (0) | 1/58 (2) | .170 |
| GEP MGUS-like | NA | NA | NA | NA | 45/139 (32) | 2/18 (11) | 44/116 (38) | .076 | 32/124 (26) | 1/3 (33) | 15/58 (26) | .958 |
Values are n/N (%), where n is number with factor and N is number with valid data for factor. NA indicates not applicable.
CR indicates complete response; sus-CR, attained and sustained through at least 3 years; los-CR, attained and lost in 3 years; non-CR, never obtained response in 3 years.
CAs at any time before enrollment.